So in May 2023 AZD0466 was still reported to perform very well:
Treatment with AZD0466 is well tolerated in pts with R/R acute leukemia, with AEs matching expected toxicity from preclinical data. Preclinical efficacy modelling and clinical PK data suggest further dose escalation is warranted to explore clinical activity.
Maybe since the last week we are listening to the prelude to taking over Starpharma.
Ann: Trading Halt, page-116
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
